Welcome to our dedicated page for BioXcel Therapeutics SEC filings (Ticker: BTAI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
BioXcel Therapeutics filings document regulatory, financing, governance, and operating disclosures for a Nasdaq-listed biopharmaceutical company focused on AI-supported drug re-innovation in neuroscience. The company’s Form 8-K reports include IGALMI regulatory updates, business and financial results, and exhibits tied to press releases and material corporate events.
The filing record also covers registered direct offerings, common stock, pre-funded warrants and accompanying warrants, credit agreement amendments, registration rights, unregistered equity issuances, and retention or milestone-based compensation arrangements. These disclosures describe BioXcel’s capital structure, contractual obligations, Nasdaq-listed common stock, and formal updates connected to its approved IGALMI product and BXCL501 development program.
BioXcel Therapeutics is conducting a registered direct offering of 2,480,294 shares of common stock and pre-funded warrants to purchase up to 2,020,491 shares, with accompanying warrants to purchase up to 4,500,785 shares.
The combined purchase price is $1.739 per share plus accompanying warrant (or $1.738 per pre-funded warrant plus warrant). Net proceeds are estimated at approximately $7.3 million after placement agent fees and expenses. Rodman & Renshaw LLC is the exclusive placement agent and will receive a 6.0% cash fee, reimbursement of certain expenses, and placement agent warrants to purchase up to 180,031 shares at an exercise price of $2.0175.
The accompanying and placement agent warrants have a five-year term and an exercise price of $1.614 (investor warrants). Shares outstanding after the offering are stated as 24,496,472 assuming full exercise of the pre-funded warrants and no exercise of accompanying or placement agent warrants. Delivery is expected on or about March 11, 2026.
BioXcel Therapeutics filed an update on its market assessment for IGALMI, its treatment for acute agitation in bipolar disorder and schizophrenia, focused on potential at-home (outpatient) use. This work is tied to a recently submitted supplemental New Drug Application seeking U.S. approval for at-home administration.
The updated opportunity analysis used results from the SERENITY At-Home clinical study, interviews with 15 prescribers and 5 payer leaders, and survey responses from 180 experienced prescribers, plus patient-level claims data to estimate how many diagnosed and treated patients might be candidates for IGALMI. The filing also highlights extensive forward-looking risks, including funding needs, substantial doubt about the company’s ability to continue as a going concern, regulatory and commercialization uncertainties, and the possibility that agitation episode volume and the total addressable market for IGALMI could be overestimated.
BioXcel Therapeutics, Inc. has an updated ownership disclosure as several Millennium-affiliated entities and Israel A. Englander filed an amended Schedule 13G reporting significant holdings of the company’s common stock. Millennium Management LLC, Millennium Group Management LLC and Mr. Englander each report beneficial ownership of 1,835,192 shares, representing 8.4% of the common stock. Integrated Core Strategies (US) LLC reports beneficial ownership of 1,833,717 shares, also representing 8.4% of the class. The filers state the securities are not held for the purpose of changing or influencing control of BioXcel Therapeutics.
BioXcel Therapeutics, Inc. entered into milestone and retention bonus agreements with certain key employees, including senior management, following its submission of a supplemental New Drug Application to the FDA for at-home treatment of agitation in bipolar disorder or schizophrenia with IGALMI®.
Each agreement provides an aggregate cash bonus of $225,000 per employee and $650,000 for the Chief Executive Officer, split between an initial lump-sum payment at signing and a final payment on April 15, 2026. The final payment depends on continued employment and the absence of a Default or Event of Default under the company’s Credit Agreement with Oaktree. The final bonus can be accelerated if the company raises at least $25 million in capital or completes a Change of Control or other material transaction before April 15, 2026, and is subject to forfeiture and repayment if the employee is terminated for Cause or resigns without Good Reason before specified 2026 dates.
BioXcel Therapeutics, Inc. filed a current report describing a key regulatory milestone for its drug IGALMI®. The company has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration seeking to expand IGALMI’s use to an at-home setting for the acute treatment of agitation associated with bipolar disorders or schizophrenia. IGALMI was previously approved in April 2022 as the first and only orally dissolving sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults under the supervision of a healthcare provider. The new sNDA aims to broaden IGALMI’s label to cover at-home use for a wider patient population, an area where the company notes there are currently no FDA-approved treatment options.
BioXcel Therapeutics, Inc. reported a new stock option grant to director Sandeep Laumas. On 01/09/2026, he received a stock option for 17,000 shares of common stock at an exercise price of $2.01 per share, expiring on 01/09/2036. The option was granted at no cost to him and is reported as directly owned, with 17,000 derivative securities beneficially owned after the transaction.
The option will vest and become exercisable on the earlier of the first anniversary of the grant date or the day immediately prior to the next annual meeting of stockholders after the grant date, provided he continues to serve as a non-employee director through that vesting date.
BioXcel Therapeutics director Rajiv Patni received a grant of 17,000 stock options on January 9, 2026. The options have an exercise price of $2.01 per share and give the right to purchase 17,000 shares of BioXcel Therapeutics common stock.
These options were reported as acquired at a price of $0 for the derivative itself, with 17,000 derivative securities beneficially owned after the transaction, all held directly. The options expire on January 9, 2036 and will vest on the earlier of the first anniversary of the grant date or the day immediately prior to the next annual meeting of stockholders, subject to Patni continuing to serve as a non-employee director through that vesting date.
BioXcel Therapeutics, Inc. granted director Peter Mueller a new stock option award. On 01/09/2026, he received an option to buy 17,000 shares of BioXcel common stock at an exercise price of $2.01 per share, expiring on 01/09/2036. The option was granted at a price of $0 for the derivative itself and is held directly by Mueller.
The option will vest and become exercisable on the earlier of the first anniversary of the grant date or the day immediately before the next annual meeting of stockholders after the grant date, as long as Mueller continues to serve as a non-employee director through that vesting date. Following this grant, he beneficially owns 17,000 stock options.
BioXcel Therapeutics director Michal Votruba received a grant of 17,000 stock options on January 9, 2026. These options give the right to purchase 17,000 shares of BioXcel Therapeutics common stock and expire on January 9, 2036. The grant is structured so that the options vest and become exercisable on the earlier of the first anniversary of the grant date or the day immediately prior to the next annual meeting of stockholders after the grant date, provided Votruba continues to serve as a non-employee director through that vesting date. After this grant, Votruba beneficially owns 17,000 derivative securities in the form of these options, held directly.
BioXcel Therapeutics director receives stock option grant
BioXcel Therapeutics, Inc. reported that director Michael Patrick Miller received a stock option award for 17,000 shares of common stock on 01/09/2026. The option has an exercise price of $2.01 per share and is held directly.
According to the vesting terms, the option will become exercisable on the earlier of the first anniversary of the grant date or the day immediately prior to the next annual meeting of stockholders after the grant date, provided he continues to serve as a non-employee director through the vesting date. Following this grant, Miller beneficially owns 17,000 stock options.